Shin Nippon Biomedical Laboratories

PPD, SNBL form Japanese clinical development joint venture

Monday, January 5, 2015

Pharmaceutical Product Development (PPD), a global CRO based in Wilmington, N.C., and Japan-based Shin Nippon Biomedical Laboratories (SNBL) have formed a joint venture to provide a full range of clinical development services in Japan, including phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services.

[Read More]

Transcept, SNBL partner for acute migraine treatment

Monday, September 30, 2013

Transcept Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of proprietary products to address therapeutic needs in neuroscience, and Shin Nippon Biomedical Laboratories (SNBL) have entered into an exclusive worldwide licensing agreement for a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine (DHE) as the active drug. 

[Read More]